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Abstract
Background: Because infiltrative cardiomyopathy and hypertrophic cardiomyopathy (HCM) share clinical and
hemodynamic features of left ventricular (LV) hypertrophy and abnormal diastolic function, it is often difficult to
distinguish these entities.
Methods: We investigated the potential role of high-sensitivity cardiac troponin T (hs-cTnT) for differentiation of
infiltrative cardiomyopathy from HCM.
Results: The study group consisted of 46 consecutive patients with infiltrative cardiomyopathies or HCM in whom
sarcomere protein gene mutations were identified at Kochi Medical School Hospital; of these, there were 11
patients with infiltrative cardiomyopathy (cardiac amyloidosis in 8 patients and Fabry disease in 3 patients) and 35
HCM patients. Serum hs-cTnT level was significantly higher in patients who had infiltrative cardiomyopathy than in
those who had HCM (0.083 ± 0.057 ng/ml versus 0.027 ± 0.034 ng/ml, p < 0.001), whereas brain natriuretic peptide
levels did not differ between the two groups. In two age-matched the 2 cohorts (patients evaluated at > 40 years at
age), hs-cTnT level, maximum LV wall thickness, posterior wall thickness, peak early (E) transmitral filling velocity,
peak early diastolic (Ea) velocity of tissue Doppler imaging at the lateral corner and E/Ea ratios at both the septal
and lateral corners were significantly different between the two groups. As for diagnostic accuracy to differentiate
the two groups by using receiver operating characteristic analysis, hs-cTnT was the highest value of area under the
curve (0.939) and E/Ea (lateral) was second highest value (0.914).
Conclusions: Serum hs-cTnT is a helpful diagnostic indicator for accurate differentiation between infiltrative
cardiomyopathy and HCM.
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Background
Infiltrative cardiomyopathies such as cardiac amyloidosis
and Fabry disease are difficult to differentiate from hyper-
trophic cardiomyopathy (HCM) because these cardiomy-
opathies share clinical and hemodynamic features of left
ventricular (LV) hypertrophy and abnormal diastolic func-
tion [1–13]. Amyloidosis is a systemic and progressive dis-
ease and frequently involves more than one organ.
Cardiac involvement in amyloidosis is the most important
prognostic factor, and when cardiac amyloidosis is the first
or main manifestation of the disease, correct diagnosis is
sometimes difficult [1–5]. Fabry disease is a relatively
prevalent cause of LV hypertrophy and is associated with
significant morbidity and early death due to heart failure
or ventricular arrhythmias [6–9, 14]. Since disease-specific
enzyme replacement therapy is now available for Fabry
disease, correct diagnosis is important [15, 16]. Although
cardiac amyloidosis and cardiac involvement in Fabry dis-
ease show concentric LV hypertrophy, LV hypertrophy is
usually asymmetric and predominantly septal in HCM,
and there is often a considerable phenotypic overlap in in-
filtrative and hypertrophic cardiomyopathies (Fig. 1) [17].
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Recently, a new generation of high-sensitivity assays
for cardiac troponins has been developed to identify
minimal cardiac damage in the setting of acute coronary
syndromes [18, 19]. Elevations of cardiac troponin levels
in high-sensitivity assays have been reported to be asso-
ciated with poor outcome in not only ischemic heart dis-
ease but also non-ischemic heart failure [20, 21].
Although high-sensitivity troponin levels seem to be dif-
ferent among various cardiomyopathies, there has been
no detailed comparison of these biomarkers’ values [22–
27]. In the present study, we investigated the potential
role of high-sensitivity cardiac troponin T (hs-cTnT) for
differentiation of infiltrative cardiomyopathy from HCM.
Methods
Subjects
The study group consisted of 46 consecutive patients
with infiltrative cardiomyopathies or HCM in whom
sarcomere protein gene mutations were identified at
Kochi Medical School Hospital; of these, there were 11
patients with infiltrative cardiomyopathy (cardiac amyl-
oidosis in 8 patients and Fabry disease in 3 patients) and
35 HCM patients. In this study, we excluded patients
with evidence of coronary artery disease and patients
with renal failure (estimated glomerular filtration rate
(eGFR) < 30 ml/min per 1.73 m2). Informed consent was
obtained from all patients or their parents in accordance
with the guidelines of the Ethics Committee on Medical
Research of Kochi Medical School.
Clinical evaluation
The diagnosis of amyloidosis was made by biopsy study
of an involved organ that demonstrated typical Congo
red birefringence when viewed under polarized light. Of
the 8 patients with cardiac amyloidosis, 2 had AL amyl-
oidosis and 6 were considered to have senile amyloidosis
with transthyretin. The diagnosis of Fabry disease was
based on low plasma alfa-galactosidase A activity, family
surveys, and tissue confirmation. The diagnosis of HCM
was based on echocardiographic demonstration of a
hypertrophied, nondilated LV (maximum LV wall thick-
ness ≥ 15 mm) in the absence of systemic hypertension
or other cardiac disease (e.g. aortic stenosis) capable of
producing clinically evident hypertrophy at some point
of clinical course. In this study, all HCM patients with
sarcomere gene mutations in whom serum hs-cTnT was
measured were enrolled. Sarcomere gene mutations in
our current study were S297X, V593fs, V762D, R945fs
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Fig. 1 Long-axis two-dimensional echocardiograms (diastole phase) of patients with cardiomyopathies. a: a cardiac amyloidosis patient with
concentric left ventricular (LV) hypertrophy, b: a cardiac amyloidosis patient with asymmetric septal hypertrophy (ASH) at first glance (but actually
concentric hypertrophy rather than ASH if moderator band is removed), c: a cardiac Fabry patient with concentric LV hypertrophy, d: a cardiac
Fabry patient with ASH (in a terminal stage patient with Fabry disease, LV systolic dysfunction with localized thinning of the base of the LV
posterior wall is seen.), e: a hypertrophic cardiomyopathy (HCM) patient with ASH, f: a HCM patient with concentric LV hypertrophy at first glance
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and R1138C in cardiac myosin-binding protein C gene,
R663C and N562K in cardiac beta-myosin heavy chain
gene, D46V in cardiac troponin T gene and R162W in
cardiac troponin I gene. These were not found in at least
200 chromosomes from healthy Japanese individuals.
There were 7 patients with dilated phase of HCM de-
fined as LV systolic dysfunction of global ejection frac-
tion (EF) < 50 %.
Evaluation of patients included medical history, clinical
examination, 12-lead electrocardiography, and conven-
tional and Doppler echocardiography. Maximum LV wall
thickness was defined as the greatest thickness in any
single segment. Left ventricular end-diastolic diameter
(LVEDD) and end-systolic diameter (LVESD) were mea-
sured from M-mode and 2-D images obtained from
parasternal long-axis views. Global EF was determined
from apical two- and four-chamber views. Mitral inflow
velocities were determined using pulsed-wave Doppler
with the sample volume positioned at the tips of the mi-
tral leaflets in the four-chamber view. Peak early (E) and
late (A) transmitral filling velocities were measured.
Tissue Doppler imaging was performed in the pulse-
Doppler mode to allow for a spectral display and record-
ing of mitral annulus velocities at septal and lateral cor-
ners. Peak early diastolic (Ea) velocity was measured,
and the E/Ea ratio was calculated. LV outflow tract gra-
dient was calculated form continuous-wave Doppler
using the simplified Bernoulli equation. LV outflow tract
obstruction was defined as the presence of basal LV out-
flow gradient ≥ 30 mmHg at rest. Right ventricular
hypertrophy was defined as thickness of right ventricular
free wall > 5 mm.
Peripheral venous blood samples were collected for
measurements of serum hs-cTnT and plasma brain natri-
uretic peptide (BNP) at the same time in clinically stable
condition. Blood was taken at a random time mainly in
our outpatient clinic. Serum hs-cTnT was measured by
Elecsys Troponin T - High Sensitive immunoassay (Roche
Diagnostics Ltd., Rotkreuz, Switzerland). The normal
range of this troponin marker in an apparently healthy
adult population is less than or equal to 0.014 ng/ml (99
percentile). Plasma BNP was measured using an enzyme
immunoassay (TOSOH II; TOSOH, Tokyo, Japan).
Statistical analysis
All data are expressed as mean ± SD or frequency (per-
centage). Differences between clinical variables of the








Age*, years 68 ± 11 57 ± 16 0.015
Gender: men, n (%) 8 (73 %) 16 (46 %) 0.118
Hs-cTnT*, ng/ml 0.083 ± 0.057 0.027 ± 0.034 <0.001
BNP*, pg/ml 349 ± 341 288 ± 378 0.322
eGFR, ml/min per 1.73 m2 61 ± 17 73 ± 21 0.090
NYHA functional class, n (%) 0.071
I 2 (18 %) 20 (57 %)
II 8 (73 %) 14 (40 %)
III 1 (9 %) 1 (3 %)
Hx. of heart failure admission,
n (%)
5 (45 %) 6 (17 %) 0.100
Atrial fibrillation, n (%) 1 (9 %) 4 (11 %) 1.00
Data are shown as mean ± SD or number (percent)
A mark of * is the results of Wilcoxon rank sum test
HCM hypertrophic cardiomyopathy, Hs-cTnT High-sensitivity cardiac troponin T,
BNP Brain natriuretic peptide, eGFR estimated glomerular filtration rate, NYHA
New York Heart Association functional class



















Fig. 2 The distribution of hs-cTnT and BNP values. Hs-cTnT: high-sensitivity cardiac troponin T, BNP: brain natriuretic peptide
Kubo et al. BMC Cardiovascular Disorders  (2015) 15:53 Page 3 of 7
infiltrative cardiomyopathy group and HCM group were
examined with univariate analysis. For analysis of con-
tinuous variables, a t-test or Wilcoxon rank sum test
was used, and a chi-square test or Fisher’s exact test was
used for analysis of categorical variables. The diagnostic
accuracies of parameters including biomarkers and
echocardiographic indices were compared by receiver
operating characteristic (ROC) analysis. Age, New York
Heart Association functional class, eGFR, E/Ea (lateral),
and hs-cTnT were included in a multivariate logistic re-
gression model to identify independent correlations of the
differentiation between the two types of cardiomyopathies.
Statistical analysis was performed using SPSS (version
14.0 J) statistical software (SPSS Japan Inc., Tokyo).
Results
Patients characteristics
Clinical characteristics of the patients in the present
study are summarized in Table 1. Patients who had infil-
trative cardiomyopathy were older than patients who
had HCM. Patients with infiltrative cardiomyopathy
were more symptomatic than patients with HCM.
Figure 2 shows the distribution of hs-cTnT and BNP
values in all patients. There was less overlap of hs-cTnT
values than BNP values between the two groups. Serum
hs-cTnT level was significantly higher in patients who
had infiltrative cardiomyopathy than in those who had
HCM, while BNP levels did not differ between the two
groups (Table 1). Table 2 shows the echocardiographic
measurements in the two groups. Maximum LV wall
thickness was smaller and posterior wall thickness was
greater in patients with infiltrative cardiomyopathy than
in those with HCM, although interventricular septal wall
thickness was not different. There was no significant dif-
ference in the LV or left atrial sizes between the two
groups. In Doppler echocardiographic measurements, E
wave velocity was higher in patients who had infiltrative








Maximum LV wall thickness, mm 17 ± 3 20 ± 4 0.021
Interventricular wall thickness, mm 16 ± 3 16 ± 4 0.628
Posterior wall thickness*, mm 15 ± 3 11 ± 2 <0.001
LV end-diastolic diameter*, mm 44 ± 5 44 ± 6 0.836
LV end-systolic diameter*, mm 32 ± 7 28 ± 7 0.118
Ejection fraction*, % 54 ± 13 62 ± 13 0.104
Left atrial diameter, mm 44 ± 6 43 ± 8 0.723
E*, cm/s 89 ± 23 69 ± 21 0.012
A, cm/s 67 ± 33 64 ± 19 0.704
E/A* 1.7 ± 1.0 1.1 ± 0.5 0.141
Dct*, msec 208 ± 81 200 ± 68 0.857
Ea septal*, cm/s 3.9 ± 1.1 5.2 ± 2.3 0.116
Ea lateral*, cm/s 4.8 ± 1.3 8.1 ± 3.5 <0.001
E/Ea septal 24 ± 7 15 ± 7 <0.001
E/Ea lateral* 20 ± 8 10 ± 4 <0.001
Presence of LVOTO, n (%) 1 (9 %) 7 (20 %) 0.658
Presence of RVH, n (%) 6 (55 %) 18 (51 %) 0.857
Data are shown as mean ± SD or number (percent)
A mark of * is the results of Wilcoxon rank sum test
HCM Hypertrophic cardiomyopathy, LV Left ventricular, LVOTO Left ventricular
outflow tract obstruction, RVH Right ventricular hypertrophy
Table 3 Clinical findings in 41 patients with cardiomyopathy







Age*, years 68 ± 11 62 ± 11 0.059
Gender: men, n (%) 8 (73 %) 13 (43 %) 0.095
Hs-cTnT*, ng/ml 0.083 ± 0.057 0.025 ± 0.031 <0.001
BNP*, pg/ml 349 ± 301 248 ± 203 0.332
eGFR, ml/min per 1.73 m2 61 ± 17 69 ± 19 0.220
NYHA functional class, n (%) 0.124
I 2 (18 %) 16 (53 %)
II 8 (73 %) 13 (43 %)
III 1 (9 %) 1 (3 %)
Hx. of heart failure admission, n (%) 5 (45 %) 6 (20 %) 0.111
Maximum LV wall thickness, mm 17 ± 3 20 ± 4 0.029
Interventricular wall thickness, mm 16 ± 3 16 ± 4 0.562
Posterior wall thickness*, mm 15 ± 3 10 ± 2 <0.001
LV end-diastolic diameter, mm 44 ± 5 45 ± 6 0.877
LV end-systolic diameter*, mm 32 ± 7 28 ± 8 0.161
Ejection fraction, % 54 ± 13 61 ± 13 0.147
Left atrial diameter, mm 44 ± 6 44 ± 9 0.950
E*, cm/s 89 ± 23 69 ± 21 0.019
A, cm/s 67 ± 33 67 ± 19 0.985
E/A* 1.7 ± 1.0 1.1 ± 0.5 0.069
Dct*, msec 208 ± 81 198 ± 70 0.825
Ea septal*, cm/s 3.9 ± 1.1 5.0 ± 2.3 0.226
Ea lateral*, cm/s 4.8 ± 1.3 7.9 ± 3.3 <0.001
E/Ea septal 24 ± 7 16 ± 7 0.002
E/Ea lateral* 20 ± 8 10 ± 4 <0.001
Presence of LVOTO, n (%) 1 (9 %) 5 (17 %) 1.000
Presence of RVH, n (%) 6 (55 %) 14 (47 %) 0.655
Data are shown as mean ± SD or number (percent)
A mark of * is the results of Wilcoxon rank sum test
HCM Hypertrophic cardiomyopathy, Hs-cTnT High-sensitivity cardiac troponin
T, BNP Brain natriuretic peptide, eGFR estimated glomerular filtration rate,
NYHA, New York Heart Association functional class, LV Left ventricular, LVOTO
Left ventricular outflow tract obstruction, RVH Right ventricular hypertrophy
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cardiomyopathy than in patients who had HCM. Ea at
the lateral corner was significantly lower and E/Ea ratios
at both the septal and lateral corners were significantly
higher in patients who had infiltrative cardiomyopathy
than in patients who had HCM.
Differentiation of the two groups in patients evaluated
at > 40 years of age
In clinical practice, phenotypic expression in infiltrative
cardiomyopathies is usually after middle-age. We therefore
focused on patients evaluated at > 40 years of age in order
to clarify the usefulness of hs-cTnT for differentiation of in-
filtrative cardiomyopathy from HCM. Table 3 shows the
clinical characteristics of the two groups of patients evalu-
ated at > 40 years of age. Hs-cTnT level, maximum LV wall
thickness, posterior wall thickness, early filling velocity, Ea
(lateral) and E/Ea ratios at both the septal and lateral cor-
ners were significantly different between the two groups.
Area under the curve values in ROC curves are shown
in Table 4. Hs-cTnT was highest and E/Ea (lateral) was
second highest to differentiate the two groups. The multi-
variate logistic regression analysis showed that the inde-
pendent determinants of the differentiation between the
two types of cardiomyopathies were hs-cTnT (p = 0.047)
and E/Ea (lateral) (p = 0.028). When the cut-off levels were
defined as hs-cTnT of 0.035 ng/ml and E/Ea (lateral) of 11,
combined measurements of these parameters resulted in
100 % sensitivity and 95 % specificity for the diagnosis of
infiltrative cardiomyopathy (Fig. 3).
Discussion
To the best of knowledge, this is the first report that a
new generation of assays, hs-cTnT, is able to differenti-
ate accurately between infiltrative cardiomyopathy, in-
cluding cardiac amyloidosis and cardiac involvement of
Fabry disease, and HCM. Serum hs-cTnT is a helpful
diagnostic indicator and should be measured in the
evaluation of patients with thickening of the LV wall.
Although the underlying cause is different, infiltrative car-
diomyopathy and HCM share clinical and hemodynamic
features of LV hypertrophy and abnormal diastolic function
[1–13]. It is often difficult to distinguish these entities by
routine clinical examinations. Diagnosis of cardiac amyloid-
osis based on conventional modalities is often only possible
once the disease is in a relatively advanced stage [1–5]. In
hemodynamic parameters on echocardiography, a restrict-
ive pattern of transmitral flow velocity, which is considered
to be characteristic for cardiac amyloidosis, is not always
observed in patients with this disease: cardiac amyloidosis
can present as an abnormal relaxation pattern, depending
on the left atrial or LV end-diastolic pressure. In Fabry dis-
ease, cardiac involvement occurs in the majority of patients
and is mainly manifested as LV hypertrophy. There have
been several reports of Fabry disease sometimes being









Maximum LV wall thickness 0.739
ROC receiver operating characteristic, AUC area under the curve, Hs-cTnT




















The distribution of hs-cTnT and E/Ea (lateral) values
Fig. 3 The distribution of hs-cTnT and E/Ea (lateral) values. Hs-cTnT: high-sensitivity cardiac troponin T, E: peak early transmitral filling velocity, Ea
(lateral): peak early diastolic velocity of mitral annulus velocities at lateral corner
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undiagnosed in HCM cohorts [6–9]. On the other hand,
clinical management differs among these cardiomyopa-
thies in terms of prognosis and treatment. Compared
with HCM, cardiac amyloidosis and Fabry disease are
more progressive and show a poorer prognosis. Further-
more, there are several effective treatments available for
these infiltrative cardiomyopathies: high-dose chemo-
therapy and stem-cell transplantation for AL amyloid-
osis and enzyme replacement therapy for Fabry disease
[15, 16, 28]. To optimize survival in patients with these
infiltrative cardiomyopathies, early diagnosis and insti-
tution of therapy are essential.
In the present study, we evaluated the value of hs-
cTnT to distinguish between infiltrative cardiomyopa-
thies and HCM. Serum hs-cTnT level is a useful marker
to differentiate two groups. The mechanisms of myocyte
injury and release of cardiac troponins in patients with
non-ischemic heart failure or cardiomyopathies remain
unresolved. Various reasons have been proposed for high
troponin levels, including increased wall stress, myocyte
damage from inflammatory cytokines or oxidative stress,
altered calcium handling, and coronary microvascular
dysfunction [29]. For the hypertrophied myocardium,
coronary microvascular dysfunction is considered to be
the most plausible mechanism for elevation of cardiac
troponins. In fact, microvascular dysfunction has been
reported in cardiac amyloidosis, Fabry disease, and
HCM [30–32]. Microvascular dysfunction and subse-
quent ischemia may be important components of the
disease progression in patients with cardiac hypertrophy.
Although the reason is unclear why hs-cTnT level is
higher in patients who had infiltrative cardiomyopathy
than in those who had HCM, we speculate that apop-
totic or necrotic injury may be induced by the toxic ef-
fect of accumulated substances themselves in infiltrative
cardiomyopathy.
In the present study, E/Ea at lateral corner (not septal
corner) was second highest in area under the curve
values in ROC curves to differentiate the two groups.
This may result from the findings that amyloid depos-
ition in cardiac amyloidosis is diffuse, whereas LV hyper-
trophy is usually asymmetric and predominantly septal
in HCM.
Limitations
There are several limitations to be acknowledged in the
present study. First, the number of subjects was small
and some of the statistical analyses might have been af-
fected. We need to have more data on hs-cTnT levels in
various clinical severities in each disease entity. A diag-
nostic challenge remains in patients with infiltrative car-
diomyopathies who have relatively mild abnormalities on
echocardiography. Second, due to the retrospective de-
sign of the study, it is possible that there is a selection
bias, although the study population consisted of con-
secutive patients with cardiomyopathies. Third, we could
not distinguish between cardiac amyloidosis and cardiac
involvement of Fabry disease within infiltrative cardio-
myopathies by using hs-cTnT measurements. This bio-
marker has not been fully evaluated in Fabry disease.
Conclusions
Measurement of serum hs-cTnT enables accurate dis-
crimination between infiltrative cardiomyopathy and
HCM. The combination of this biomarker and conven-
tional echocardiographic parameters helps to differenti-
ate these cardiomyopathies.
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